current P/S is an unimpressive 49.36. The overall Major Pharmaceuticals group has an average P/S ratio of 43.63, which is significantly worse than the sector’s 11.66. traded at an unexpectedly high

Bellicum Pharmaceuticals Stock News

Bellicum Pharmaceuticals Announces Proposed $5'. ...

Stocks That Hit 52-Week Lows Of Monday

The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Stocks That Fell Through 52-Week Lows Wednesday

The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Bellicum Pharmaceuticals Q2 EPS $(0.58) Misses $(0.54) Estimate, Sales $1.39M Beat $870K Estimate

Stocks That Set New 52-Week Lows Friday Morning

Bellicum Pharmaceuticals (BLCM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Bellicum: Ready To Transition Into A Commercial-Stage Company

The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

Bellicum Pharma S-3 Shows Registration For $400M Mixed Securities Offering

Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Worst Value Picks Now: Bellicum Pharmaceuticals, Inc. (BLCM), Lululemon Athletica Inc. (LULU) | Post Analyst

Bellicum Pharmaceuticals Announces Rivo-cel Achieved Primary Endpoint In Pediatric Registrational Trial

The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Top Fintech Company